other material
confidence high
sentiment positive
materiality 0.80
Cellectar presents iopofosine I 131 MM data: 32% ORR at optimal dose >60 mCi TAD
Cellectar Biosciences, Inc.
- Overall response rate 23% in 64 evaluable patients; 32% ORR at optimal >60 mCi TAD dose.
- Clinical benefit rate 75% and disease control rate 85.7% at >60 mCi TAD.
- Triple-class refractory patients achieved 46% ORR (median PFS 3.4 mo); quad-class 50% ORR.
- Grade 3/4 cytopenias common (62.5% thrombocytopenia, anemia, neutropenia); no off-target toxicities.
- Drug given as four 15-min IV infusions over 3 months with low-dose dexamethasone.